Funko Inc vs Novavax Inc — how do they compare? Funko Inc trades at $6.03 (market cap $332.33M), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 3.9× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| FNKO | NVAX | |
|---|---|---|
Market Cap | $332.33M | $1.31B |
Sector | Consumer Staples | Health |
52-Week High | $6.35 | $11.19 |
52-Week Low | $2.65 | $6.22 |
Enterprise Value | $552.98M | $889.30M |
Signals from Pluang's Aura AI — not financial advice
FNKO trades at $5.86, down 5.33% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving average support, while oscillators are neutral. Fundamentally, revenue declined to $908.21M in 2025 with a net loss of $67.36M, though recent quarters have beaten EPS estimates. The company maintains a low P/S of 0.35 and appointed a new Chief Commercial Officer in August 2026 to drive growth.
Outlook is cautiously optimistic with improving EBITDA guidance and analyst buy ratings, but risks include persistent net losses, high debt levels, and competitive pressures in the collectibles market. The stock's valuation discount offers potential if profitability strengthens.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Trailing returns across standard periods
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →